Secukinumab shows significant efficacy in nail psoriasis: week 32 results from the TRANSFIGURE study

Kristian Reich, John Sullivan, Peter Arenberger, Ulrich Mrowietz, Sasha Jazayeri, Matthias Augustin, Anne Parneix, Pascaline Regnault, Ruquan You & Marina Milutinovic
Background: Nail psoriasis is associated with decreased finger mobility, functional impairment, pain, reduced quality of life [ref:1] and is often resistant to available therapies [ref:2]. It correlates with more severe psoriatic disease and is an important predictor of PsA [ref:3].[for full text, please go to the a.m. URL]
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.